Print

Aradigm Corporation And Canadian Department Of National Defence Extend AERx Liposomal Ciprofloxacin Development Program  
4/26/2006 12:41:57 PM

Aradigm Corporation (NASDAQ: ARDM) today announced that Defence R&D Canada (DRDC) has extended the development program for the aerosolized delivery of liposome-encapsulated ciprofloxacin as a treatment for bioterror-related anthrax.
//-->